LONDON--(BUSINESS WIRE)--Market research firm Technavio has announced the release of their latest report on the global autoimmune drugs market. This new report will provide expert market insights for the forecast period 2018-2022.
The new report will follow up on Technavio’s previous report, providing an up-to-date analysis of the market concerning the current market scenario, latest trends and drivers, and the overall global environment. The report will also provide new predictions for the forecast period, including the changes in the demand-supply shifts in different regions.
The upgraded research report on the global autoimmune drugs market is an integral part of central nervous system portfolio. Technavio covers an extensive range of market research reports on the central nervous system market, covering different regions and top industry segments. Some of the trending topics include myelodysplastic syndrome, central nervous system disorders therapeutics, regenerative medicine, and protein therapeutics.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Save more with Technavio. Buy 2 reports and get the third for FREE: View all Technavio’s current offers
Global market opportunities
Technavio’s previous report on the global autoimmune drugs market projected that in terms of regional dominance, the Americas led the global market during 2015 by accounting for a market share of nearly 52%. This trend is expected to continue until the end of 2020. The expanded access to medical care because of health care reforms is expected to be a major factor to propel the growth prospects of this market.
In the previous report, a senior research analyst at Technavio stated, “The increasing popularity and dominance of biologics in the pharma market are some of the major factors driving the growth of the autoimmune drugs market. Biologics drugs used in the treatment of autoimmune diseases are protein derivatives, which block the action of chemicals that cause inflammation of joints. The rising focus on understanding the disease at the molecular level will boost the use of biologics in treating autoimmune diseases. Some biologics used to treat autoimmune diseases are adalimumab, certolizumab, etanercept, golimumab, and infliximab. Also, biologics have not only outpaced the sales of branded pharmaceuticals but also account for over 18% of the global pharmaceutical sales.”
Technavio’s new report on the global autoimmune drugs market will evaluate the key geographical regions and their behavior over the past four years, introducing new data and observations and providing new predictions.
Looking for the latest information on the global autoimmune drugs market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Detailed analysis at your fingertips
Some of the topics that will be revisited in the new report include:
- Market size and growth rate through 2022
- Key factors driving the market growth
- Competitive landscape and revenue share analysis of the key players
- Market opportunities and factors hampering growth
Technavio’s report on the global autoimmune drugs market for the period 2018-2022 is available to order now and will be delivered within one week of purchase.
|
Technavio’s best deals of the month! Technavio supports Health for All campaign on this World Health Day with 20% savings on all reports in the Health and Wellness category for the entire month. OR Celebrate International Astronomy Day by indulging in a whopping 30% savings on all reports in the Space category. Offer valid from 16th April for a limited period. |
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
